Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Milvexian in Hepatic Impairment
NCT02982707Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of milvexian in thrombosis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 5 days, Area under the plasma concentration-time curve from time zero extrapolated to infinite time up to 5 days and 2 more. Started Mar 2018; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02982707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982707.